Touchlight is at the forefront of innovation in gene editing technology with our groundbreaking MegaBulb DNA (mbDNA). This novel, circular, single-stranded DNA template is poised to transform the landscape of gene therapy and CRISPR applications.

In this article, Elena Stoyanova, Ph.D., Senior Scientist, and Tom Adie, Ph.D., Associate Director of Research, explore how mbDNA is overcoming limitations of traditional DNA templates and viral vectors, offering a high-purity, synthetic alternative for precise and efficient gene editing.

The mbDNA Advantage

• High-purity, synthetic ssDNA templates
• Enhanced efficiency and minimal toxicity
• Capacity for multi-kilobase sequences
• Compatibility with various CRISPR nucleases
• Scalable production

As a pioneer in enzymatic DNA synthesis, Touchlight is leveraging its expertise to meet the growing demand for effective, non-viral gene therapies. Our mbDNA technology is attracting significant interest from leading pharmaceutical and biotechnology firms, demonstrating its potential to revolutionise gene editing applications.

Access the article to learn more about how mbDNA is setting new standards for diverse gene therapy applications and making treatments safer and more accessible.